Amy Tara Waldman, M.D., M.S.C.E.
Associate Professor of Neurology at the Children's Hospital of Philadelphia
Medical Director, Leukodystrophy Center of Excellence, Children's Hospital of Philadelphia
Associate Director of Neurology Gene Therapy, Children's Hospital of Philadelphia
Department: Neurology
Contact information
Children's Hospital of Philadelphia
Division of Neurology
3401 Civic Center Boulevard
Philadelphia, PA 19104
Division of Neurology
3401 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-590-1719
Fax: 215-590-1771
Fax: 215-590-1771
Email:
waldman@chop.edu
waldman@chop.edu
Education
B.A. (Chemistry)
Johns Hopkins University, 1997.
M.D. (Medicine)
Jefferson Medical College, 2002.
M.S.C.E. (Epidemiology)
Perelman School of Medicine at the University of Pennsylvania, 2011.
B.A. (Chemistry)
Johns Hopkins University, 1997.
M.D. (Medicine)
Jefferson Medical College, 2002.
M.S.C.E. (Epidemiology)
Perelman School of Medicine at the University of Pennsylvania, 2011.
Post-Graduate Training
Pediatric Intern, Children's Hospital of Philadelphia, 2002-2003.
Pediatric Resident, Children's Hospital of Philadelphia, 2003-2004.
Neurology Resident, Children's Hospital of Philadelphia and Hospital of the University of Pennsylvania, 2004-2007.
Multiple Sclerosis Fellow, Children's Hospital of Philadelphia and Hospital of the University of Pennsylvania, 2007-2009.
Pediatric Intern, Children's Hospital of Philadelphia, 2002-2003.
Pediatric Resident, Children's Hospital of Philadelphia, 2003-2004.
Neurology Resident, Children's Hospital of Philadelphia and Hospital of the University of Pennsylvania, 2004-2007.
Multiple Sclerosis Fellow, Children's Hospital of Philadelphia and Hospital of the University of Pennsylvania, 2007-2009.
Certifications
American Board of Psychiatry and Neurology, 2008.
American Board of Psychiatry and Neurology - Maintenance of Certification, 2018.
Permanent linkAmerican Board of Psychiatry and Neurology, 2008.
American Board of Psychiatry and Neurology - Maintenance of Certification, 2018.
Selected Publications
Virupakshaiah A, Schoeps VA, Chang G, Waltz M, Race J, Mar S, Francisco C, Casper TC, Rose J, Rodriguez M, Tillema JM, Chitnis T, Gorman MP, Benson LA, Graves JS, Rensel M, Abrams A, Krupp LB, O'Neill KA, Lotze TE, Aaen G, Wheeler Y, Schreiner T, Waldman AT, Chong J, Titcomb TJ, Tremlett H, Waubant E: Longitudinal stability of dietary intake patterns in pediatric-onset multiple sclerosis: A multicenter prospective cohort study. Multiple Sclerosis and Related Disorders 115: 107677, Nov 2026.Virupakshaiah A, Schoeps VA, Race J, Gambrah-Lyles C, Chang G, Waltz M, Nasr P, Moseley CE, Zamvil SS, Edwards AR, Francisco C, Casper TC, Rose JW, Flanagan EP, Rodriguez M, Tillema JM, Chitnis T, Gorman MP, Benson LA, Graves JS, Rensel M, Abrams AW, Krupp LB, O'Neill KA, Lotze TE, Fisher KS, Shukla NM, Aaen GS, Wheeler YS, Schreiner TL, Waldman AT, Chong J, Waubant E, Mar SS: Comparative Effectiveness of Treatments for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Neurology 107(8): e218508, Oct 2026.
Vietzen H, Waubant EL, Casper TC, Benson LA, Chitnis T, Schreiner T, Waldman AT, Mar S, Weinstock-Guttman B, Kühner LM, Berger SM, Graninger M, Rostásy K, Saucke H, Kauth F, Koukou G, Sommer S, Wendel EM, Bsteh G, Ponleitner M, Reindl M, Kornek B, Breu M, Puchhammer-Stöckl E, Rommer P, Berger T: Impaired control of autoimmunity increases pediatric multiple sclerosis risk in EBNA-1-seropositives and -seronegatives. Proceedings of the National Academy of Sciences 123(40): e2607529123, Oct 2026.
Abrams A, Gambrah-Lyles, C, Otto S, Meeks H, Casper C, Rose J, Gombolay G, Yang J, Waubant E, Lotze T, Chitnis T, Graves J, Krupp L, Benson LA, MacRae R, Rensel M, Tillema JM, Schreiner T, Ness J, Rodriguez M, O'Neill K, Shukla N, Chang G, Wright M, Waldman A, Mar S : Exploring Long Term Outcomes and Quality of Life in Pediatric Onset MS. American Committee on Treatment and Research in Multiple Sclerosis-European Committee on Treatment and Research in Multiple Sclerosis Meeting, Toronto, Canada Oct 2026.
Raviola Murataj1, Gina Chang1, Vinicius Andreoli Schoeps1, Akash Virupakshaiah2, Charles Casper3, Gregory Aaen4, Bianca Weinstock-Guttman5, Jennifer Graves6, Soe Mar7, Tanuja Chitnis8, Yolanda Wheeler9, Tim Lotze10, Teri Schreiner11, Amy Waldman12, Catherine Lee1, Iona Cheng1, Emmanuelle Waubant1: Elevated Air PM2.5 Levels Are Associated with Increased Clinical Activity in Pediatric-Onset MS. American Committee on Treatment and Research in Multiple Sclerosis-European Committee on Treatment and Research in Multiple Sclerosis Meeting, Toronto, Canada Oct 2026.
Gavazzi F, Woidill S, Sevagamoorthy A, Jawad AF, D’Aiello R, Bradford J, Lerner M, Hong P, White A, Tashnim Z, Cusack SV, Glanzman AM, Harrington A, Waldman AT, Vanderver A, Adang L: Design of a pediatric low motor function item battery in leukodystrophies. Annals of Neurology 100(S36): S116, Oct 2026 Notes: Presented at the Child Neurology Society Annual Meeting, Montreal, Quebec, Canada
Kymes S, Roberts A, Waldman A, Williams K, Collins A, Bernarde J, Matter E, Savar S, Bernard G, Keller SR, Cunningham C, Eichler F, Hacochen Y, Sampson J, Currlin W, Hazel S, Lee L, Vera-Llonch1 M, for the ION373-CS1 research group: In-trial interviews to explore the experience of individuals with Alexander disease in the zilganersen phase 3 clinical trial. Annals of Neurology 100(S36): S129-S130, Oct 2026 Notes: Presented at the Child Neurology Society Annual Meeting, Montreal, Quebec, Canada
Kymes S, Vera Llonch M, Chen C, Waldman A, Ruiz Santiago N, Collins A.: Reduction in frequency of all-cause hospitalizations from the ION373-CS1 clinical trial of zilganersen in the treatment of individuals with Alexander disease. Annals of Neurology 100(S36): S119, Oct 2026 Notes: Presented at the Child Neurology Society Annual Meeting, Montreal, Quebec, Canada.
Waldman AT, Tonduti D, van der Knaap MS, Bernard G, Eichler F, Sampson JB, Zerem A, Chataway J, Cunningham C, Bertini E, Nicita F, Hacohen Y, Saito T, Keller SR, Vaia Y, Kim NN, van Haren K, Nagy A, van den Berg E, Bruschi F, Lynch DS, Chen C, Ruiz-Santiago N, Yarlas A, Cowling BS, Collins A, Smith AV: Efficacy and safety of zilganersen, an investigational RNA-targeted antisense therapy, in people living with Alexander disease: additional data from the pivotal phase 1-3 trial. Annals of Neurology 100(S36): S74-75, Oct 2026 Notes: Presented at the Child Neurology Society Annual Meeting, Montreal, Quebec, Canada.
Yarlas A, Maher S, Llonch MV, Kymes S, Vilcot T, Collins A, Waldman A, on behalf of the ION373-CS1 Study Team: Psychometric Evaluation of the 10-Meter Walk Test in Alexander Disease (AxD): Findings from the ION373-CS1 study. Annals of Neurology 100(S36): S119-S120, Oct 2026 Notes: Child Neurology Society Annual Meeting, Montreal, Quebec, Canada.